ReviewFrontiers in immunology2026
Tislelizumab plus chemotherapy followed by anlotinib maintenance therapy in a patient with extensive-stage small cell lung cancer and intracranial recurrence after palliative whole-brain radiotherapy: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases. It is characterized by an exceptionally high proliferative rate, a strong propensity for early metastasis, and a poor prognosis. The median overall survival (OS) following brain metastases development in extensive-stage SCLC (ES-SCLC) was 10.5 months. Herein, a 74-year-old Chinese male was initially diagnosed with ES-SCLC with synchronous hepatic metastases. Following four cycles of first-line chemotherapy comprising etoposide and carboplatin, the patient underwent thoracic radiotherapy (TRT); however, prophylactic cranial irradiation was not performed. Brain metastases were detected 19 months after TRT, prompting initiation of palliative whole-brain RT (WBRT). Intracranial disease recurrence was observed five months after completion of WBRT. Managing intracranial recurrence following palliative WBRT in patients with ES-SCLC is clinically challenging. In this case of intracranial recurrence following palliative WBRT, the patient received second-line therapy comprising tislelizumab in combination with irinotecan and cisplatin chemotherapy, followed by anlotinib as maintenance therapy, achieving a complete response, sustained status of no evidence of disease for 24 months, and an OS of 67 months. Based on this case, tislelizumab combined with chemotherapy followed by anlotinib maintenance therapy represents a potentially viable treatment strategy for patients with recurrent intracranial lesions following palliative WBRT who have not received prior immune checkpoint inhibitor therapy. However, given the limited evidence derived solely from a single case, the clinical utility of this regimen requires validation in prospective and controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.